Four Biotechs Face Challenges Amid U.S. COVID-19 Vaccine Funding CutsFDAU.S. COVID-19 vaccine biotechs face funding cuts, regulatory changes, and operational challenges. Learn how Vaxart, Novavax, GeoVax, and CastleVax navigate this uncertain landscape impacting future pandemic preparedness.
Biogen and City Therapeutics Forge $1B RNAi PartnershipBiogenBiogen has partnered with RNAi specialist City Therapeutics in a deal worth up to $1 billion to develop next-generation CNS drugs. The collaboration includes milestone payments, equity investment, and clinical development leadership.
Psychedelic Trial Shows 94% Remission RateGilgamesh PharmaceuticalGilgamesh Pharmaceuticals’ GM-2505 achieved a 94% remission rate in a Phase 2a trial for major depressive disorder. The short-acting psychedelic showed significant, sustained improvements and favorable safety in 40 patients.
FDA Halts Rocket’s Gene Therapy Trial After FatalityFDARocket Pharmaceuticals faces an FDA clinical hold on its gene therapy trial for Danon disease following a patient death. The company is reassessing its approach and extending its financial runway into 2027.
Biotech Cuts Jobs Despite $350M FundingBiotechEikon Therapeutics raised $350M in 2025 to advance its drug pipeline, including Chinese-licensed assets, but recently announced a 15% layoff due to reduced U.S. research funding.
Samsung Biologics to Spin Off Biosimilars UnitSamsung BiologicsSamsung Biologics plans to spin off its biosimilars subsidiary, Samsung Bioepis, by October 2025 to address conflict-of-interest concerns and enhance investor value, while continuing strong growth in its CDMO business.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
